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Summary: Fibrinogen and factor XIII were measured in sixty-four women with recently detected gynaecological
tumours. Twenty-six of these tumours were benign and 32 were malignant: of the last group, nine patients had
metastases. No patient showed clinical signs of bleeding or thrombosis. A reference group consisted of 31 age-
matched healthy women. For fibrinogen, no significant deviation between the patient groups and the control group
was found. The median values of factor XIII were higher in the benign tumour group than in the control group. In
patients with a gynaecological tumour and metastases, factor XIII was significantly lower than in the non-metasta-
sized malignancy group or in the benign tumour group.
From a clinical point of view, the determination of the factor XIII activity might be helpful in diagnosing metastases
in patients with a gynaecological tumour.
Introduction
Since an enzymatic assay for pläsma factor XIII activity
became available, pläsma factor concentrations
have been measured in various clinical conditions:
Crohn's disease (1), colitis ulcerösa (2), systemic
haematological disorders (7), morbus Hennoch-
Schönlein (3), bacterial infections (3) and several types
of neoplastic malignancies (4, 5, 6). Little is known
about the role of factor XIII in cancer (3). Factor XIII
has been found in connective tissue stroma (7), where it
may cross-link fibrin to the surface of neoplastic cells
without decreasing their viability (8), and provide striu>
türal integrity and vascularization support to the tumour
mass (9). It has been reported that thrombin and factor
XIII show mitogenic activity towards some malignant
cell types in vitro (10), There are, to our knowledge,
no reports on the behaviour of plasmatic factor XIII in
gynaecological oiieology. Therefore, it was the aim of
this study to investigate factor XIII in pläsma of patients
with benign and malignant gynaecological tumours.
Simultaneously the acute phase reactant fibrinogeni was
determined to assess whether plasmatic factor XIII may
also behave like an acute phase protein.
Materials and Methods
Patients
Plasma samples were collected from 58 patients with a benign or
malignant gynaecologicial tumour. The diagnosis was later con-
firmed by histology. On admission to the hospital no patient
showed clinical signs of bleeding or thrombosis. Twenty-six pa-
tients had a benign disease (tab. 1) and 32 patients a malignancy
(tab. 2). In the latter group nine patients had histologically proven
metastases, mostly in lymph nodes or peritoneal tissue. The use of
medication was excluded. A reference group consisted of 31 age-
matehed subjectively healthy women.
Samples
The Coagulation constituents were determined in citrated pläsma
prepared by centrifugation of nine volumes of freshly drawn blood
with one volume trisodium citräte (0. i l mol/1) for 10 min (1600 g)
at 25 °C. The pläsma was stored at -70 °C in plastic tubes and
thawed with tap water at 37 °C for 5 min before serial analysis.
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Methods
Fibrinogen was cletermined with a clotting assay (Merz and Dade)
according to the method of Clattss, measured by means of a
Schnittger and Gross coagulometer. Factor XIII was determined
with a photometric assay of Behring Corporation (Marburg, Ger-
many). The Mann-Whitney U test and the %2-test, where appropri-
ate, were used for statistical analysis.
Results
In table l the basic characteristics of the patients with a
benign disease are given. Ovarian cysts occur mostly in
this group.
Table 2 shows the various tumour types in the patients
with a malignancy. Most of the patients appeared to have
a cervix or an ovarian carcinoma. Metastases were espe-
cially present in the ovarian carcinoma group.
In table 3 a comparison of the benign tumour group, the
total malignant tumour group and an age-matched con-
trol group is given. Except for age, the quantities
showed a non-Gaussian distribution, and the results are
presented äs median values and interquartile ranges. Tlie
group with a benign gynaecological tumour showed sta-
tistically significant, higher median values for factor
XIII, compared with the age-matched control group. The
median value for factor XIII in the malignant tumour
group was not significantly different from that in the
age-matched control group.
In table 4, patients of the malignancy group with and
without metastases are compared with the benign tu-
Tab. l Basic patient characteristics of the benign tumour group.
Benign tumour type Patients
Ovarian/adnex cyst
Ovarian fibroma
Ovarian cyst and myoma uteri
Endometrioma
Myoma uteri











































mour group. A significant decrease of factor XIII values
was seen in the group with metastases.
Table 5 gives the percentages of decreased and increased
values of fibrinogen and factor XIII in the three patient
groups, based on the laboratqry reference ranges. The
values of fibrinogen did not show a statistically signifi-
cant difference.
A significant proportion of the factor XIII values were
decreased in the metastasis group, compared with the
other two patient groups.
Discussion
No significant differences were found in the fibrinogen
levels of patients with a benign or malignant gynaecolo-
gical tumour, nor in any of these groups compared with
the control group.
Factor XIII values in patients with a benign gynaecolo-
gical tumour and in patients with a non-metastasized
malignant tumour, however, were significantly enhanced
in comparison with the control group. An explanation
for this phenomenon might be that additional tissue
factor XIII is released from these tumours. This possi-
bility is strengthened by a recent review by Aeschliman F
& Paulsson (11), on the localization and function of i
factor XIII, in which it is shown that tissue factor XIII is
nearly ubiquitous. Factor XIII values were significantly
decreased in patients with metastases compared with the
patients without metastases and the patients with benign
tumours. This finding might be relevant, since factor
XIII is important for the cross-linking of proteins other
than fibrin. Lowered factor XIII concentrations have
been reported in malignant melanoma,. breast cancer and
gastric cancer (4, 5, 12), but decreased factor XIII has
not been found in patients with hing cancer or colonic
cancer (13, 14).
An explanation for the decrease might be the consuriip-
tion of factor XIII during the cross-linking of proteins
in and around the tumour. Consumption during locäl ac-
tivation of the clotting system promotes tumour mainte·-
nance and perpetuation by conversion of fibrinogen to
fibrin (9). Moreover, factor XIII is used for the cross-
linking oif fibrin and a2-antiplasmin to the surface of
neoplastic cells (7, 8), which promotes tumour growth
and prevents fibrinolytic degradation. The presenee of
thrombin and factor XIII on the tumour site may there-
fore contribute to tumour progression (10). In an earlier
study it was established that patients with a metastasized -
gynaecological tumour displäyed high levels of coagula-
tion activation and reactive fibrinolysis. Therefore, re-
dueed plasma factor XIII concentrations may at least
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Tab. 3 Comparison of the benign and total malignant tumour groups with an age-matched control
group.
Patients with benign Total patient group









































n. s. n. s. n. s.
n. s. n. s. n. s.
n. s. 0.002 n. s.
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Tab. 5 Percentage of decreased and iiicreased values of various
coagulatipn and fibrinolysis constituents based on laboratory refer-
ence ranges.
The significant values are indicated (%2-test): !) p = 0.005; 2) p =

































pärtly be due to enhanced consumption for cröss^linking
purposes. In addition, the factor XIII reduction may be
the result of enhanced unspecific proteolysis by e. g.
neutrophil elastase. Low activities of factor XIII have
been reported in other diseases with increased elastase-
tti-antitrypsin complexes (15, 16, 17). An enhanced pro-
teolyis of factor XIII in patients with metastases is pos-
sible, since an elevation of the proteolytic activity has
also been reported in tumour patients.
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In conclusion, factor XIII and fibrinogen did not behave
synchronously in the different gynaecological tumour
groups. This finding does not support the idea that factor
XIII might possess acute phase charactertistics. For the
clinician, however, the determination of factor XIII may
provide an aid to the diagnosis of inetastasis in pätients
with gynaecological tumours.
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